These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 11426843

  • 61. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat.
    Beaulieu1 P, Bisogno1 T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS.
    Eur J Pharmacol; 2000 May 19; 396(2-3):85-92. PubMed ID: 10822060
    [Abstract] [Full Text] [Related]

  • 62. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
    Fride E.
    Neuro Endocrinol Lett; 2004 May 19; 25(1-2):24-30. PubMed ID: 15159678
    [Abstract] [Full Text] [Related]

  • 63. Exogenous anandamide protects rat brain against acute neuronal injury in vivo.
    van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K.
    J Neurosci; 2001 Nov 15; 21(22):8765-71. PubMed ID: 11698588
    [Abstract] [Full Text] [Related]

  • 64. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
    Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V.
    Endocrinology; 2000 Jan 15; 141(1):118-26. PubMed ID: 10614630
    [Abstract] [Full Text] [Related]

  • 65. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation.
    Randall MD, Kendall DA.
    Eur J Pharmacol; 1997 Sep 24; 335(2-3):205-9. PubMed ID: 9369375
    [Abstract] [Full Text] [Related]

  • 66. Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice.
    Baskfield CY, Martin BR, Wiley JL.
    J Pharmacol Exp Ther; 2004 Apr 24; 309(1):86-91. PubMed ID: 14718593
    [Abstract] [Full Text] [Related]

  • 67. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.
    Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G.
    Proc Natl Acad Sci U S A; 2003 Feb 04; 100(3):1393-8. PubMed ID: 12538878
    [Abstract] [Full Text] [Related]

  • 68. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells.
    Basavarajappa BS, Hungund BL.
    J Neurochem; 1999 Feb 04; 72(2):522-8. PubMed ID: 9930723
    [Abstract] [Full Text] [Related]

  • 69. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth.
    Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V.
    FASEB J; 2001 Dec 04; 15(14):2745-7. PubMed ID: 11687506
    [Abstract] [Full Text] [Related]

  • 70. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide.
    Di Marzo V, Breivogel C, Bisogno T, Melck D, Patrick G, Tao Q, Szallasi A, Razdan RK, Martin BR.
    Eur J Pharmacol; 2000 Oct 20; 406(3):363-74. PubMed ID: 11040343
    [Abstract] [Full Text] [Related]

  • 71. Regulation of subthalamic neuron activity by endocannabinoids.
    Morera-Herreras T, Ruiz-Ortega JA, Taupignon A, Baufreton J, Manuel I, Rodriguez-Puertas R, Ugedo L.
    Synapse; 2010 Sep 20; 64(9):682-98. PubMed ID: 20336631
    [Abstract] [Full Text] [Related]

  • 72. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
    Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC.
    J Pharmacol Exp Ther; 2002 Jun 20; 301(3):1020-4. PubMed ID: 12023533
    [Abstract] [Full Text] [Related]

  • 73. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats.
    Jamshidi N, Taylor DA.
    Br J Pharmacol; 2001 Nov 20; 134(6):1151-4. PubMed ID: 11704633
    [Abstract] [Full Text] [Related]

  • 74. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
    Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM.
    FASEB J; 2000 Jul 20; 14(10):1432-8. PubMed ID: 10877836
    [Abstract] [Full Text] [Related]

  • 75. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor.
    Murillo-Rodríguez E, Cabeza R, Méndez-Díaz M, Navarro L, Prospéro-García O.
    Neuroreport; 2001 Jul 20; 12(10):2131-6. PubMed ID: 11447321
    [Abstract] [Full Text] [Related]

  • 76. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.
    Williams CM, Kirkham TC.
    Pharmacol Biochem Behav; 2002 Jul 20; 71(1-2):333-40. PubMed ID: 11812541
    [Abstract] [Full Text] [Related]

  • 77. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
    Tanda G, Loddo P, Di Chiara G.
    Eur J Pharmacol; 1999 Jul 02; 376(1-2):23-6. PubMed ID: 10440085
    [Abstract] [Full Text] [Related]

  • 78. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
    Massi P, Fuzio D, Viganò D, Sacerdote P, Parolaro D.
    Eur J Pharmacol; 2000 Jan 17; 387(3):343-7. PubMed ID: 10650181
    [Abstract] [Full Text] [Related]

  • 79. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
    Maneuf YP, Nash JE, Crossman AR, Brotchie JM.
    Eur J Pharmacol; 1996 Jul 18; 308(2):161-4. PubMed ID: 8840127
    [Abstract] [Full Text] [Related]

  • 80. Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
    Costa B, Giagnoni G, Colleoni M.
    Psychopharmacology (Berl); 2000 Apr 18; 149(2):121-8. PubMed ID: 10805606
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.